See every side of every news story
Get Started
SubscribeLogin
Donald Trump
Everton
Volodymyr Zelenskyy
Ukraine War
Hamas
Viktor Orbán
Basketball
Israel-Hamas Conflict
Elon Musk
Javier Milei
Manchester United
Vladimir Putin
Published • loading... • Updated

Multiomic Profiling of T Cell Lymphoma after Therapy with Anti-BCMA CAR T Cells and GPRC5D-Directed Bispecific Antibody

Summary by Stemwell Science News
Scientists reported a 63-year-old male who received ciltacabtagene autoleucel chimeric antigen receptor (CAR) T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. [Nature Medicine] Abstract
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
Stemwell Science NewsStemwell Science News

Multiomic Profiling of T Cell Lymphoma after Therapy with Anti-BCMA CAR T Cells and GPRC5D-Directed Bispecific Antibody

Scientists reported a 63-year-old male who received ciltacabtagene autoleucel chimeric antigen receptor (CAR) T cells and the GPRC5D × CD3 bispecific talquetamab for early relapse of his multiple myeloma. [Nature Medicine] Abstract

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Stemwell Science News broke the news in on Friday, February 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

News
For You
Search
BlindspotLocal